FDA

 

     *FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients.

The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart attack or blockages in the arteries to the legs.

                                           see more (8/5/2014)

 *FDA approves Zykadia(ceritinib) for late-stage lung cancer.

The U.S. Food and Drug Administration today granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC).

​see more(29/4/2014)

*FDA approves Sylvant(siltuximab) for rare Castleman’s disease.

​The U.S. Food and Drug Administration today approved Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes).   See more (23/4/2104)​

 *FDA approves Cyramza( ramucirumab) for stomach cancer.

 See more (21/4/2014)>>

     *FDA Approved Tanzeum (albiglutide) for the treatment of adultswith type 2 diabetes. ​

​

*FDA approves first sub​lingual allergen extract for the treatment of certain grass pollen allergies.

The U.S. Food and Drug Administration recently approved Oralair to treat allergic rhinitis (hay fever) with or without conjunctivitis (eye inflammation) that is induced by certain grass pollens in people ages 10 through 65 years. Oralair is the first sublingual (under the tongue) allergen extract approved in the United States. After administration of the first dose at the health care provider’s office, where the patient can be observed for potential adverse reactions, Oralair can be taken at home.

 See more (2/4/2014) >>

*FDA approves Topamax for migraine prevention in adolescents.

the U.S. Food and Drug Administration approved Topamax (topiramate) for prevention (prophylaxis) of migraine headaches in adolescents ages 12 to 17. This is the first FDA approval of a drug for migraine prevention in this age group. ​See more (28/3/2014)>>

*FDA​ approves first long-acting recombinant coagulation Factor IX concentrate for patients with Hemophilia B.

The U.S. Food and Drug Administration today approved Alprolix, Coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and children who have Hemophilia B. Alprolix is the first Hemophilia B treatment designed to require less frequent injections when used to prevent or  reduce the frequency of bleeding.​ See more (28/3/2014)>>

​*FDA approves Otezla to treat psoriatic arthritis​.​

The U.S. Food and Drug Administration today approved Otezla (apremilast) to treat adults with active psoriatic arthritis (PsA).The safety and effectiveness of Otezla, an inhibitor of phosphodieasterase-4 (PDE-4), were evaluated in three clinical trials , See More(21/3/2014)>>​

 *FDA approves Myalept (metreleptin for injection) to treat rare metabolic disease.

   The U.S. Food and Drug Administration approved Myalept (metreleptin for injection) as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. ​See More (25/2/2014)>> ​

*FDA approves Northera(droxidopa)to treat neurogenic orthostatic hypotension.

The U.S. Food and Drug Administration today approved Northera capsules (droxidopa) for the treatment of neurogenic orthostatic hypotension (NOH). NOH is a rare, chronic and often debilitating drop in blood pressure upon standing that is associated with Parkinson's disease, multiple-system atrophy, and pure autonomic failure.  See More(18/2/2014)​>>​​

 *FDA approves Mekinist in combination with Tafinlar for advanced melanoma

This week the U.S. Food and Drug Administration approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage).See More(10/1/2014)>>​

 *FD​A approves Farxiga to treat type 2 diabetes.

The U.S. Food and Drug Administration today approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.​ See More (8/1/2014)>>​

*FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation​.

FDA is warning that using more than one dose in 24 hours of over-the-counter (OTC) sodium phosphate drugs to treat constipation can cause rare but serious harm to the kidneys and heart, and even death.​see more (8/1/2014)>>

​​​*FDA approves Tretten to treat rare genetic clotting disorder​​​

The U.S. Food and Drug Administration today approved Tretten, Coagulation Factor XIII A-Subunit (Recombinant), the first recombinant product for use in the routine prevention of bleeding in adults and children who have a rare clotting disorder, known as congenital Factor XIII A-subunit deficiency.​ see more  (23/12/2013) >>​​

 * Methylphenidate ADHD Medications: Drug Safety Communication - Risk of Long-lasting Erections​​

In 12/17/2013 the FDA is warning that methylphenidate products, one type of stimulant drug used to treat attention deficit hyperactivity disorder (ADHD), may in rare instances cause prolonged and                 sometimes painful erections known as priapism.see more>>